Prostate cancer (hormone relapsed, metastatic) - enzalutamide (after docetaxel) [ID600]: appeal announcement
An appeal has been lodged for this appraisal, however it was rejected. Below are the papers related to this appeal.
More information on the Technology Appraisal Appeal Process.
This page was last updated: 22 July 2014